Litigation Details for AstraZeneca AB v. Glenmark Generics Ltd. (D. Del. 2014)
✉ Email this page to a colleague
AstraZeneca AB v. Glenmark Generics Ltd. (D. Del. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-05-23 |
| Court | District Court, D. Delaware | Date Terminated | 2015-04-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 7,951,400 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Glenmark Generics Ltd.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for AstraZeneca AB v. Glenmark Generics Ltd. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2014-05-23 | 1 | product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … THE ’400 PATENT 14. On May 31, 2011, the U.S. Patent and Trademark Office …copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and enforceable…includes ONGLYZA® together with the’400 patent and U.S. Patent No. RE44,186, which covers the composition | External link to document | |
| 2014-09-23 | 21 | than April 15, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028).Thirty Month Stay Deadline… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2014 14 April 2015 1:14-cv-00665 830 Patent None District Court, D. Delaware | External link to document | |
| 2015-04-14 | 30 | Without Prejudice of Formulation Patent Claims (U.S. Patent No. 7,951,400) Between AstraZeneca and Glenmark…2014 14 April 2015 1:14-cv-00665 830 Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
